Reason for request
Inclusion on the list of medicines approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit is substantial. |
Clinical Added Value
| important |
In view of the results obtained in a population with an unfavourable prognosis and the size of the effect observed, the Transparency Committee considers that TORISEL provides a substantial improvement in actual benefit (IAB level II) compared with interferon alpha (ROFERON-A) in advanced renal cell carcinoma patients with at least 3 of the 6 prognostic risk factors. |
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
zcvkaqV1NpQ18PCD
